Yanzhen Guo

Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial

Xiangrui Meng, Tao Wu, Yonggui Hong et al. · ˜The œLancet. Gastroenterology & hepatology · 2022 · 86 citations

Medicine, Oncology, Pharmacology +11

Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study

Shun Lü, Jianying Zhou, Hong Jian et al. · The Lancet Respiratory Medicine · 2023 · 71 citations

Medicine, Oncology, Pharmacology +14

Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase–Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma

Xinhua Wang, Lei Zhang, Xiangli Liu et al. · JAMA Oncology · 2022 · 58 citations · Full text

Medicine, Oncology, Pharmacology +13

Pancreatic fistula after pancreaticoduodenectomy: Risk factors and preventive strategies

Gang Liu, Jianshu Chen, Tianran Li et al. · Journal of Cancer Research and Therapeutics · 2019 · 49 citations · Full text

Medicine, Clinical Sciences, Surgery +17

MicroRNA-96-5p represses breast cancer proliferation and invasion through Wnt/β-catenin signaling via targeting CTNND1

Xiaohui Gao, Yali Zhang, Zhiye Zhang et al. · Scientific Reports · 2020 · 38 citations · Full text

Life Sciences, Molecular Biology, Oncology +17